{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:29:49Z","timestamp":1787020189339,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>As many as 30% of critically ill patients in intensive care units experience acute liver dysfunction with hyperbilirubinemia as a part of multiorgan failure that is associated with poor outcome. This retrospective cohort study was aimed at comparing CytoSorb and ADVOS in terms of bilirubin removal and overall survival among critically ill patients with hyperbilirubinemia\u2009\u2265\u20097\u00a0mg\/dL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>At the University Hospital Essen, between January 2021 and March 2024, 71 patients were treated with CytoSorb integrated in a continuous veno-venous hemodiafiltration (CVVHDF) circuit, and 71 patients were treated with ADVOS. Each therapy session lasted 24\u00a0h. We separately analyzed the subgroup of patients with acute-on-chronic liver failure (ACLF), in which 31 patients were treated with CytoSorb and 66 patients were treated with ADVOS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The first single sessions of both CytoSorb with CVVHDF and ADVOS were associated with a statistically significant decrease in total serum bilirubin levels (Cytosorb, 20 to 14\u00a0mg\/dL,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001; ADVOS, 16 to 14\u00a0mg\/dL,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), but the percentage bilirubin reduction was more pronounced for CytoSorb treatment (26% vs. 17%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0002). The number of days of treatment was similar for both groups (3 vs. 4,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.07). After completion of therapy, serum levels of total bilirubin had decreased significantly; 19.9 to 11.3\u00a0mg\/dl (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) in the CytoSorb group and 16.3 to 14.0\u00a0mg\/dL (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003) in the ADVOS group. The relative bilirubin reduction was significantly higher after application of CytoSorb than after treatment with ADVOS (35% (IQR 19,54) vs. 15% (IQR \u2212\u200911;54),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Regarding patients with ACLF, relative reduction of bilirubin after the first session as well as after the completion of liver support was significantly higher among patients who were treated with CVVHDF and CytoSorb than among those patients who received ADVOS. The relative removal of creatinine and urea nitrogen was significantly higher after ADVOS treatment than after CytoSorb with CVVHDF treatment considering all critically ill patients as well as ACLF patients. Seven-day or in-hospital mortality rates were high among critically ill patients and patients with ACLF in both liver support groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results showed that CytoSorb and CVVHDF treatment performed better than ADVOS in bilirubin removal among critically ill patients with hyperbilirubinemia caused by acute liver dysfunction and in the subgroup of patients with ACLF. ADVOS was more efficient in eliminating creatinine and urea nitrogen than was CVVHDF with CytoSorb. Additional prospective randomized controlled trials are warranted to investigate the efficacy of hemoperfusion with CytoSorb for liver disease indications among critically ill patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-025-04342-6","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T17:44:51Z","timestamp":1754329491000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Artificial liver support with Cytosorb and continuous veno-venous hemodiafiltration versus advanced organ support (ADVOS) for critically ill patients with hyperbilirubinemia and acute-on-chronic liver failure (ACLF)"],"prefix":"10.1186","volume":"26","author":[{"given":"Kristina","family":"Sch\u00f6nfelder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa Katharina","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kribben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Jahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Tyczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justa","family":"Friebus-Kardash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"issue":"3","key":"4342_CR1","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/00365521.2021.2005136","volume":"57","author":"S Jonsdottir","year":"2022","unstructured":"Jonsdottir S, Arnardottir MB, Andresson JA, Bjornsson HK, Lund SH, Bjornsson ES. Prevalence, clinical characteristics and outcomes of hypoxic hepatitis in critically ill patients. Scand J Gastroenterol. 2022;57(3):311\u20138.","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"4342_CR2","doi-asserted-by":"publisher","first-page":"420","DOI":"10.4037\/aacnacc2016324","volume":"27","author":"A Grek","year":"2016","unstructured":"Grek A, Arasi L. Acute liver failure. AACN Adv Crit Care. 2016;27(4):420\u20139.","journal-title":"AACN Adv Crit Care"},{"issue":"1","key":"4342_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/biomedicines12010067","volume":"12","author":"C Turan","year":"2023","unstructured":"Turan C, Szigetv\u00e1ry CE, K\u00f3i T, Engh MA, Atakan I, Zubek L, et al. Hemoadsorption therapy for critically ill patients with acute liver dysfunction: A Meta-Analysis and systematic review. Biomedicines. 2023;12(1):67.","journal-title":"Biomedicines"},{"issue":"3","key":"4342_CR4","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1159\/000047017","volume":"20","author":"R Jalan","year":"2002","unstructured":"Jalan R, Williams R. Acute-on-chronic liver failure: pathophysiological basis of therapeutic options. Bllod Purif. 2002;20(3):252\u201361.","journal-title":"Bllod Purif"},{"issue":"17","key":"4342_CR5","doi-asserted-by":"publisher","first-page":"3932","DOI":"10.12998\/wjcc.v11.i17.3932","volume":"11","author":"P Papamichalis","year":"2023","unstructured":"Papamichalis P, Oikonomou KG, Valsamaki A, Xanthoudaki M, Katsiafylloudis P, Papapostolou E, Skoura A, et al. Liver replacement therapy with extracorporeal blood purification techniques current knowledge and future directions. World J Clin Cases. 2023;11(17):3932\u201348.","journal-title":"World J Clin Cases"},{"issue":"1","key":"4342_CR6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s13054-022-04163-1","volume":"26","author":"R Perez","year":"2022","unstructured":"Perez R, de Garibay A, Leonhardt J, Zipprich A, Bauer M. Critical care hepatology: definitions, incidence, prognosis and role of liver failure in critically ill patients. Crit Care. 2022;26(1):289.","journal-title":"Crit Care"},{"issue":"Suppl S8","key":"4342_CR7","doi-asserted-by":"publisher","first-page":"S258","DOI":"10.21037\/atm.2019.12.79","volume":"7","author":"M Kluge","year":"2019","unstructured":"Kluge M, Tacke F. Liver impairment in critical illness and sepsis: the dawn of new biomarkers? Ann Transl Med. 2019;7(Suppl S8):S258.","journal-title":"Ann Transl Med"},{"issue":"4","key":"4342_CR8","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1097\/01.CCM.0000259462.97164.A0","volume":"35","author":"L Kramer","year":"2007","unstructured":"Kramer L, Jordan B, Druml W, Bauer P, Metnitz P, DEAA for the Austrian Epidemiologic Study on Intensive Care, ASDI Study Group. Incidence and prognosis of early hepatic dysfunction in critically ill patients\u2014A prospective multicenter study. Crit Care Med. 2007;35(4):1099\u2013104.","journal-title":"Crit Care Med"},{"issue":"1","key":"4342_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1089-3261(03)00134-X","volume":"8","author":"RH Moseley","year":"2004","unstructured":"Moseley RH. Sepsis and cholestasis. Clin. Liver Dis. 2004;8(1):83\u201394.","journal-title":"Liver Dis"},{"issue":"7","key":"4342_CR10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","volume":"22","author":"JL Vincent","year":"1996","unstructured":"Vincent JL, Moreno R, Takala J, Willatts S, De Mendon\u00e7a A, Bruining H, et al. The SOFA (Sepsis-related organ failure Assessment) score to describe organ dysfunction\/failure. On behalf of the working group on Sepsis-Related problems of the European society of intensive care medicine. Intensive Care Med. 1996;22(7):707\u201310.","journal-title":"Intensive Care Med"},{"issue":"8","key":"4342_CR11","doi-asserted-by":"publisher","first-page":"e0255230","DOI":"10.1371\/journal.pone.0255230","volume":"16","author":"HS Han","year":"2021","unstructured":"Han HS, Park CM, Lee DS, Sinn DH, Gil E. Evaluating mortality and recovery of extreme hyperbilirubinemia in critically ill patients by phasing the peak bilirubin level: a retrospective cohort study. PLoS ONE. 2021;16(8):e0255230.","journal-title":"PLoS ONE"},{"issue":"4","key":"4342_CR12","doi-asserted-by":"publisher","first-page":"e94479","DOI":"10.1371\/journal.pone.0094479","volume":"9","author":"KL Ong","year":"2014","unstructured":"Ong KL, llison MA, Cheung BM, Wu BJ, Barter PJ, Rye KA. The relationship between total bilirubin levels and total mortality in older adults: the united States National health and nutrition examination survey (NHANES) 1999\u20132004. PLoS ONE. 2014;9(4):e94479.","journal-title":"PLoS ONE"},{"issue":"3","key":"4342_CR13","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/TP.0000000000003364","volume":"105","author":"EM Weiss","year":"2021","unstructured":"Weiss EM, Saner FM, Asrani SKM, Biancofiore GM, Blasi A, Lerut JM, et al. When is a critically ill cirrhotic patient too sick to transplant? Development of consensus criteria by a multidisciplinary panel of 35 international experts. Transplantation. 2021;105(3):561\u20138.","journal-title":"Transplantation"},{"issue":"5","key":"4342_CR14","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1111\/jgh.15255","volume":"36","author":"R Tandon","year":"2021","unstructured":"Tandon R, Froghi S. Artificial liver support systems. J Gastroenterol Hepatol. 2021;36(5):1164\u201379.","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"4342_CR15","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s00134-018-5464-6","volume":"45","author":"EC Poli","year":"2019","unstructured":"Poli EC, Rimmele T, Schneider AG. Hemoadsorption with CytoSorb\u00ae. Intensive Care Med. 2019;45(2):236\u20139.","journal-title":"Intensive Care Med"},{"issue":"21","key":"4342_CR16","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.3390\/jcm10215182","volume":"10","author":"K Ocskay","year":"2021","unstructured":"Ocskay K, Tomescu D, Faltlhauser A, Jacob D, Friesecke S, Malbrain M, et al. Hemoadsorption in liver indication\u2019-analysis of 109 patients data from the cytosorb international registry. J Clin Med. 2021;10(21):5182.","journal-title":"J Clin Med"},{"issue":"7","key":"4342_CR17","doi-asserted-by":"publisher","first-page":"e24653","DOI":"10.1097\/MD.0000000000024653","volume":"100","author":"V Fuhrmann","year":"2021","unstructured":"Fuhrmann V, de Garibay APR, Faltlhauser A, Tyczynski B, Jarczak D, Lutz J, et al. Registry on extracorporeal multiple organ support with the advanced organ support (ADVOS) system. Med (Baltim). 2021;100(7):e24653.","journal-title":"Med (Baltim)"},{"issue":"1","key":"4342_CR18","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13613-020-00714-3","volume":"10","author":"V Fuhrmann","year":"2020","unstructured":"Fuhrmann V, Weber T, Roedl K, Motaabbed J, Tariparast A, Jarczak D, et al. Advanced organ support (ADVOS) in the critically ill: first clinical experience in patients with multiple organ failure. Ann Intensive Care. 2020;10(1):96.","journal-title":"Ann Intensive Care"},{"issue":"1","key":"4342_CR19","doi-asserted-by":"publisher","first-page":"10190","DOI":"10.1038\/s41598-021-89712-4","volume":"11","author":"C Scharf","year":"2021","unstructured":"Scharf C, Liebchen U, Paal M, Becker-Pennrich A, Irlbeck M, Zoller M, et al. Successful elimination of bilirubin in critically ill patients with acute liver dysfunction using a cytokine adsorber and albumin dialysis: a pilot study. Sci Rep. 2021;11(1):10190.","journal-title":"Sci Rep"},{"issue":"1","key":"4342_CR20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13613-023-01198-7","volume":"13","author":"A Greimel","year":"2023","unstructured":"Greimel A, Habler K, Gr\u00e4fe C, Maciuga N, Brozat CI, Vogeser M, et al. Extracorporeal adsorption of protective and toxic bile acids and bilirubin in patients with cholestatic liver dysfunction: a prospective study. Ann Intensive Care. 2023;13(1):110.","journal-title":"Ann Intensive Care"},{"issue":"1","key":"4342_CR21","doi-asserted-by":"publisher","first-page":"11309","DOI":"10.1038\/s41598-024-61658-3","volume":"14","author":"P Haselwanter","year":"2024","unstructured":"Haselwanter P, Scheiner B, Balcar L, Semmler G, Riedl-Wewalka M, Schmid M, et al. Use of the cytosorb adsorber in patients with acute-on-chronic liver failure. Sci Rep. 2024;14(1):11309.","journal-title":"Sci Rep"},{"issue":"8\u20139","key":"4342_CR22","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1177\/03913988231191952","volume":"46","author":"O Sommerfeld","year":"2023","unstructured":"Sommerfeld O, Neumann C, Becker J, von Loeffelholz C, Roth J, Kortgen A, et al. Extracorporeal albumin dialysis in critically ill patients with liver failure: comparison of four different devices-A retrospective analysis. Int J Artif Organs. 2023;46(8\u20139):481\u201391.","journal-title":"Int J Artif Organs"},{"issue":"4","key":"4342_CR23","doi-asserted-by":"publisher","first-page":"e0249342","DOI":"10.1371\/journal.pone.0249342","volume":"16","author":"L Kaps","year":"2021","unstructured":"Kaps L, Ahlbrand CJ, Gadban R, Nagel M, Labenz C, Klimpke P, et al. Applicability and safety of discontinuous advanced organ support (ADVOS) in the treatment of patients with acute-on-chronic liver failure (ACLF) outside of intensive care. PLoS ONE. 2021;16(4):e0249342.","journal-title":"PLoS ONE"},{"issue":"2","key":"4342_CR24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/1751143718772789","volume":"20","author":"VD Dhokia","year":"2019","unstructured":"Dhokia VD, Madhavan D, Austin A, Morris CG. Novel use of cytosorb\u2122 haemadsorption to provide biochemical control in liver impairment. J Intensiv Care Soc. 2019;20(2):74\u2013181.","journal-title":"J Intensiv Care Soc"},{"issue":"6","key":"4342_CR25","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.3390\/jcm12062258","volume":"12","author":"M Popescu","year":"2023","unstructured":"Popescu M, David C, Marcu A, Olita MR, Mihaila M, Tomescu D. Artificial liver support with cytosorb and MARS in liver failure: A retrospective propensity matched analysis. J Clin Med. 2023;12(6):2258.","journal-title":"J Clin Med"},{"issue":"5","key":"4342_CR26","doi-asserted-by":"publisher","first-page":"E101","DOI":"10.1111\/aor.13864","volume":"45","author":"A Alharthy","year":"2021","unstructured":"Alharthy A, Faqihi F, Memish ZA, Balhamar A, Nasim N, Shahzad A, et al. Continuous renal replacement therapy with the addition of cytosorb cartridge in critically ill patients with COVID-19 plus acute kidney injury: A case-series. Artif Organs. 2021;45(5):E101\u201312.","journal-title":"Artif Organs"},{"key":"4342_CR27","first-page":"3737083","volume":"2019","author":"HM Al-Dorzi","year":"2019","unstructured":"Al-Dorzi HM, Alhumaid NA, Alwelyee NH, Albakheet NM, Nazer R, Aldakhil SK, et al. Anemia, blood transfusion, and filter life span in critically ill patients requiring continuous renal replacement therapy for acute kidney injury: A Case-Control study. Crit Care Res Pract. 2019;2019:3737083.","journal-title":"Crit Care Res Pract"},{"issue":"4","key":"4342_CR28","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3390\/jcm11041031","volume":"11","author":"R Ju\u00e1rez-Vela","year":"2022","unstructured":"Ju\u00e1rez-Vela R, Andr\u00e9s-Esteban EM, Gea-Caballero V, S\u00e1nchez-Gonz\u00e1lez JL, Marcos-Neira P, Serrano-L\u00e1zaro A, et al. Related factors of Anemia in critically ill patients: A prospective multicenter study. J Clin Med. 2022;11(4):1031.","journal-title":"J Clin Med"},{"issue":"10","key":"4342_CR29","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.3390\/jcm11102782","volume":"11","author":"L Kaps","year":"2022","unstructured":"Kaps L, Schleicher EM, Montano CM, Bros M, Gairing SJ, Ahlbrand CJ, et al. Influence of advanced organ support (ADVOS) on cytokine levels in patients with Acute-on-Chronic liver failure (ACLF). J Clin Med. 2022;11(10):2782.","journal-title":"J Clin Med"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04342-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04342-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04342-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T14:20:33Z","timestamp":1757341233000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04342-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4342"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04342-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6195702\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"10 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and was approved by the Ethics Committee of the University Hospital Essen (23-11563-BO, 23-11170-BO). The consent to participate was waived by the local ethics committee of the University Duisburg-Essen (23-11563-BO, 23-11170-BO) due to the retrospective analyses that deal with data obtained from clinical routine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"432"}}